PurposeEncodes the drug-preservable Cas9-NS3-NLS/VPR, which can be used to activate gene expression when combined with an NS3 inhibitor and appropriately designed sgRNA.
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||112244||Standard format: Plasmid sent in bacteria as agar stab||1||$75|
This material is available to academics and nonprofits only.
- Backbone size w/o insert (bp) 5500
- Total vector size (bp) 12204
Modifications to backboneHygromycin resistance
Vector typeMammalian Expression
Growth in Bacteria
Copy numberHigh Copy
Insert Size (bp)6700
MutationNS3 mutant T54A
- Promoter CMV
/ Fusion Proteins
- HA (C term on NS3)
- AU1 (N term on NS3)
- Cloning method Gibson Cloning
- 5′ sequencing primer CMV-Forward
- 3′ sequencing primer BGH-Reverse (Common Sequencing Primers)
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:dCas9-NS3-NLS/VPR was a gift from John Ngo (Addgene plasmid # 112244 ; http://n2t.net/addgene:112244 ; RRID:Addgene_112244)
For your References section:Chemogenetic control of gene expression and cell signaling with antiviral drugs. Tague EP, Dotson HL, Tunney SN, Sloas DC, Ngo JT. Nat Methods. 2018 Jul;15(7):519-522. doi: 10.1038/s41592-018-0042-y. Epub 2018 Jul 2. 10.1038/s41592-018-0042-y PubMed 29967495